Clinical Research Article
Expression and the clinical significance of apolipoprotein B mRNA editing enzyme catalytic polypeptide 3G (APOBEC3G) in peripheral blood mononuclear cell of patients with chronic hepatitis B
Jianjun Wang, Ping Zhao, Xueyuan Jin, Yongqian Cheng, Tao Yan, Honghong Liu, Liang Wu
Published 2018-02-15
Cite as Chin J Exp Clin Infect Dis (Electronic Edition), 2018, 12(1): 56-60. DOI: 10.3877/cma.j.issn.1674-1358.2018.01.011
Abstract
ObjectiveTo investigate the differences between the levels of apolipoprotein B mRNA editing enzyme catalytic polypeptide 3G (APOBEC3G) in different stages of HBV infection and during the different periods treated with different antiviral drugs, and to speculate on the role of innate immunity in antiviral therapy.
MethodsTotal of 30 cases of chronic hepatitis B (CHB) who were treated with polyethylene glycol interferon alpha-2a and 30 patients treated with entecavir were selected, 20 patients with CHB and 20 patients with hepatitis B cirrhosis were selected; while 20 healthy adults collected as controls. The HBV DNA load and ALT levels were detected, and the level of APOBEC3G mRNA in peripheral blood mononuclear cells (PBMCs) was analyzed by fluorescence quantitative PCR.
ResultsCompared with healthy cases, during the period of using entecavir and interferon of patients with CHB and liver cirrhosis and antiviral. The levels of APOBEC3G mRNA in patients’ PBMCs were increased by 1.4 times (t =-3.166, P = 0.003), 1.37 times (t =-2.206, P = 0.0335), 1.44 times (t =-3.381, P = 0.0014) and 3.95 times (t = -4.790, P = 0.0002) . There was no significant difference in the levels of APOBEC3G mRNA between the patients treated with entecavir and the patients without any treatment (t =-0.242, P = 0.8097). The levels of APOBEC3G mRNA in patients treated with interferon was 2.36 times (t = 4.085, P = 0.0002), 2.40 times (t = 4.9, P < 0.0001) as that in patients without any treatment and patients treated with entecavir, respectively. The levels of APOBEC3G mRNA in patients with high levels of ALT was 1.35 times higher than that of patients with normal level of ALT (t = 2.667, P = 0.0112). The levels of HBV DNA was not related to the content of APOBEC3G mRNA (F = 0.2124, P = 0.8871).
ConclusionsAPOBEC3G plays an important role in the antiviral therapy of interferon.
Key words:
Apolipoprotein B mRNA editing enzyme catalytic polypeptide 3G (APOBEC3G); Chronic hepatitis B; Antiviral therapy
Contributor Information
Jianjun Wang
International Treatment Centre of Liver Diseases, The 302 Hospital of PLA, Beijing 100039, China
Ping Zhao
Xueyuan Jin
Yongqian Cheng
Tao Yan
Honghong Liu
Liang Wu